Login
Navigate Fool.com
Will INSM beat
the market?

INSMED, INC.

NASDAQ: INSM

Community Rating: 2 Stars: Unattractive

14.03 -0.01 (-0.07%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $13.96
Previous Close $14.04
Daily Range $13.50 - $14.12
52-Week Range $7.27 - $22.29
Market Cap $550.9M
P/E Ratio -8.78
Dividend (Yield) $0.00 (0.0%)
Volume 488,086
Average Daily Volume 1,183,713
Current FY EPS -$1.69

How do you think INSM
will perform against the market?

Top INSM Bull/Bear Pitches

 

zzlangerhans (< 20)
Submitted November 11, 2011

Insmed stock has been volatile since the company first reported in August that the FDA had placed their phase III antibiotic on clinical hold due to a cancer signal in rat studies. The looming predica … More

0 Replies Reply Report this Post
 

obiwankenobe1250 (< 20)
Submitted March 3, 2007

Voraciously consuming an inordinate amount of cash relative to its revenues. Long term prospects had better pan out, because the near term looks pretty dismal. And besides, downwithpumpers provided … More

0 Replies Reply Report this Post

News & Commentary

Which Biotech Blow-Up Is a Bad-News Buy?

These two biotechs bombed bad on Thursday. Which one would make an interesting buy today?

Mid-Day Market Update: Nordion Surges On Acquisition News; BlackBerry Shares Decline

This Week in Biotech: Biogen Idec Gets a Key Approval While Insmed Confuses Investors

An FDA approval, a terrible review from regulators on a breakthrough therapy designated drug, and a trio of mid-stage clinical data are this week's top biotech stories.

Why Insmed Incorporated Shares Sank

Insmed shares tumble after reporting mixed phase 2 results. Is this dip a buying opportunity or a cue to keep your distance?

Healthcare Stocks Extending Rebound; Insmed Slammed After Inhaled Antibiotic Fails in Early-Stage Te

Healthcare Stocks Extending Rebound; Insmed Slammed After Inhaled Antibiotic Fails in Early-Stage Testing

Sector Update: Healthcare

Today’s Top Biotech Stories: Insmed, Exelixis, United Therapeutics, and Alnylam

Insmed, Exelixis, United Therapeutics, and Alnylam could all make biotech headlines this morning. Here’s why.

Healthcare Stocks Finishing in the Red; Insmed Climbs to 4-Year High on U.S., EU Patent Grants

Sector Update: Healthcare

Our BioPharma Catalyst Watch List

See More INSM News...

Sector

Healthcare

Industry

Drugs

INSMED, INC. (INSM) Description

A biopharmaceutical company focused on the development and commercialization of drugs to treat metabolic diseases, endocrine disorders and oncology within niche markets that have unmet medical needs. Website: http://www.insmed.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks